Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Trane Technologies | Synopsys | Pfizer | |
|---|---|---|---|
| Moat rating | narrow Trane's FY2025 Form 10-K (filed 5 February 2026) makes exactly one rank claim about itself and it is hedged: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services'. It sits inside a Competitive Conditions section that opens 'Our products and services are sold in highly competitive markets throughout the world', describes 'a wide variety of competitors that vary by product line and services' including 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and names price first among 'the principal methods of competition in these markets', ahead of quality, delivery, service and support, technology and innovation. The risk factors push the same way: 'The markets that we serve are highly competitive', 'consolidation and new entrants (including non-traditional competitors) within our industries' 'could result in increased competition and pricing pressures', Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located', and 'some of our competitors may employ pricing and other strategies that are not traditional'. What the filing does evidence is an advantage that gets paid for: 2025 net revenues of $21,321.9 million, up 7.5% from $19,838.2 million, of which the company's own bridge assigns 3.0 points to pricing; gross margin up 50 basis points to 36.2%; operating income of $3,967.4 million, 18.6% of revenues; and firm backlog up to $7,769.4 million from $6,747.7 million. But that advantage is not uniform in the same document: the EMEA pricing component was (0.3)% and its segment adjusted EBITDA margin fell 150 basis points to 18.3%, and Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'. A position the company itself will only call 'one of the leading', defended in markets it calls highly competitive and priced unevenly across its three segments, is protection that is real but bounded. | wide The FY2025 10-K positions Synopsys as 'a global leader in supplying the mission-critical EDA solutions' and, after the Ansys merger, 'the global leader in engineering S&A software' — two adjacent franchises the filing says now sit in one portfolio. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs The filing rules out the obvious alternative in its own words. Item 1's Patents and Licenses paragraph says the Company 'does not consider any single patent, trademark, copyright, trade secret, proprietary technology, technical data, business process or any other confidential information (or any related group of any such items) to be of material importance to any segment or to the business as a whole', and the matching risk factor is blunter: 'we do not believe that our business is materially dependent on a single intellectual property right or any group of them. In our opinion, engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' That is a company disclaiming an IP moat. Where the 10-K does locate durability is the installed equipment and the channel wrapped around it. The overview frames the entire growth plan that way - 'As an industry leader with an extensive global install base, our growth strategy includes expanding recurring revenue through services and rental options' - the principal products and services table carries 'Service agreements', 'Repair and maintenance services', 'Parts and supplies (aftermarket and OEM)' and 'Rental services' alongside the equipment itself, the Distribution paragraph puts U.S. sales through Trane's own 'branch sales offices, distributors and dealers across the country' and non-U.S. sales through 'numerous subsidiary sales and service companies with a supporting chain of distributors throughout the world', and the accounting policy confirms the contracts are multi-period: 'For extended warranties and long-term service agreements, revenue for these distinct performance obligations are recognized over time on a straight-line basis over the respective contract term.' Long-lived equipment serviced under term agreements by the manufacturer's own branches is the asset this filing keeps pointing at, which is why the moat is read as an installed-base tie rather than a patent estate. | switching costs The 10-K describes EDA as 'mission-critical' software licensed mostly as network licences across a customer's whole design flow, with post-contract support providing 'frequent updates to maintain the utilization of the software due to rapid changes in technology' — a dependence that renews at every process node. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader The company's own claim is comparative but never exclusive: 'We are one of the leading manufacturers in the world of HVAC systems and services and transport temperature control products and services' - one of, with no rank, no share figure and no competitor named anywhere in the filing. Competitive Conditions sets that against 'well-established regional or specialized competitors, as well as larger U.S. and non-U.S. corporations or divisions of larger companies', and the risk factors add that Trane competes 'with large companies and with smaller, local operators who may have customer, regulatory or economic advantages in the geographies in which they are located'. The scale behind the claim is substantial and disclosed - $21,321.9 million of 2025 net revenues, products sold in approximately 100 countries, backlog of $7,769.4 million - but the 10-K never asserts the top position in any market it serves. | co leader The 10-K claims global leadership in EDA while stating 'The EDA industry is highly competitive' and that Synopsys competes against other EDA vendors and against customers' own internally developed design tools. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Price is a separately disclosed component of growth in this filing and it is positive: of the 7.5% increase in 2025 net revenues, the company's bridge assigns 3.0% to pricing against 3.2% volume, 0.8% acquisitions and 0.5% currency, and gross margin rose 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'. In the Americas the price component was 3.8% of an 8.0% revenue increase, and that segment's adjusted EBITDA margin rose 70 basis points to 21.6% 'primarily due to price realization and gross productivity, partially offset by inflation and continued business reinvestment'. What holds the band below strong is in the same bridge and the same risk factors: EMEA pricing was (0.3)% and its segment margin fell 150 basis points to 18.3%; Asia Pacific pricing was 0.4% on organic revenue down 2.5%; consolidation and new entrants 'could result in increased competition and pricing pressures'; and 'in the event there is deflation, we may experience pressure from our customers to reduce prices.' Price that sticks in the Americas, disappears in EMEA and is disclaimed as durable in the risk factors is moderate rather than strong. | moderate The 10-K lists 'license terms, price and payment terms' among the principal competitive factors and states 'No single factor drives an EDA customer's buying decision'; licence fees depend on licence type, product mix and the number of copies licensed. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Trane Technologies is the Trane and Thermo King equipment maker - the FY2025 10-K opens by calling it 'a global climate innovator' selling HVAC, transport refrigeration and custom refrigeration through 'our strategic brands, Trane® and Thermo King®' - organised in three regional segments that produced 2025 net revenues of $17,168.8 million (Americas), $2,802.1 million (EMEA) and $1,351.0 million (Asia Pacific), with 'Approximately 25% of our net revenues in 2025 ... derived outside the U.S.' across 'approximately 100 countries' and 'no single external customer that accounted for more than 10% of our consolidated net revenues in 2025, 2024 or 2023'. The filing is candid that the markets are contested and equally candid that its position does not rest on intellectual property: 'engineering, production skills and experience are more responsible for our market position than our patents and/or licenses.' The durable asset it does describe is the installed base and the aftermarket attached to it - an 'extensive global install base' whose monetisation through 'services and rental options' is the stated growth strategy, reached through branch sales offices, dealers and distributors, with service agreements, repair and maintenance, aftermarket and OEM parts and rental all listed among the principal products. The 2025 financials carry that signature: revenues up 7.5% to $21,321.9 million split 3.2 points volume, 3.0 points price, 0.8 points acquisitions and 0.5 points currency; gross margin up 50 basis points to 36.2% 'primarily due to gross productivity and price realization, partially offset by inflation'; and backlog of $7,769.4 million on equipment where 'orders for specialized equipment or specific customer applications are submitted with extended lead times'. The limits are in the same filing. Price contributed 3.8% in the Americas but (0.3)% in EMEA and 0.4% in Asia Pacific; EMEA's segment adjusted EBITDA margin fell 150 basis points to 18.3%; Asia Pacific organic revenue fell 2.5% on 'lower volumes in China'; the Americas' otherwise strong year was 'partially offset by weaker volume in our Residential business'; and the risk factors warn that refrigerant regulation 'could make some of our existing HVAC and refrigeration products non-compliant or obsolete', with the company 'developing and selling our next generation products that utilize lower global warming potential solutions' against $347.6 million of 2025 research and development spending. For the AI build-out specifically, the link exists in the filing but is unsized: 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' appear in the principal products and services table, and those four entries are the only places the phrase occurs anywhere in the 10-K - no revenue, no ranking, no share, and no mention at all in the MD&A discussion of 2025 growth. | Synopsys sells the sign-off tools (PrimeTime static timing, IC Validator physical verification) and the silicon-proven IP that chip designs are built against, and the FY2025 Ansys merger added the multiphysics sign-off products (RedHawk-SC, Totem-SC) to the same portfolio, growing headcount about 40% to roughly 28,000. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Trane sits on the facility side of the AI build-out rather than in the compute stack. Its FY2025 10-K lists 'Data center HVAC systems', 'Data center liquid cooling solutions', 'Data center facility controls' and 'Data center services' among its principal products and services, alongside 'Thermal energy storage' and 'Smart and AI-enabled services'. Those four entries are the only occurrences of the phrase in the entire filing: there is no data center revenue figure, no ranking, no named competitor and no separate reporting - segment disclosure stops at Americas, EMEA and Asia Pacific, and the MD&A attributes the Americas' 7.4% organic growth to 'realization of price increases and higher volumes led by strong demand within our Commercial HVAC business' without naming an end market. | Design-and-IP layer feeding both the chip designers and, post-Ansys, the systems companies that simulate the products those chips go into. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |